earticle

영어

Biopharmaceuticals such as proteins and peptides usually show short half life in human and require frequent dosing for clinical application. To overcome this problem, new platform technologies for half life extension of biological drugs have been developed and applied to actual drugs for developing 2nd generation products. Most popular half life extension technologies are pegylation, hyperglycosylation, microsphere, and fusion proteins, and several products using these technologies are already in the market. In spite of the 2nd generation products which are already in the market, there are further needs for advanced platform technology to overcome
the limitations of 2nd generation products, i.e., insufficient duration and efficacy, lack of patient compliance due to large needle size, unfavorable cost of goods, and so on. Hanmi has been developing next generation biological products based on inhouse platform technology named Lapscovery Technology. Lapscovery technology is consisted of carrier conjugation of biologics through non-peptidyl linker and is clearly differentiated from other technologies in the duration of products, efficacy, and patient compliance. Hanmi is continuing development of 5 LAPS-products in preclinical and clinical stages using this platform technologies. In this lecture, the overview of Lapscovery technology as well as the competing technologies will be presented. In addition, the future prospects of bio-better and bio-similar products including technical and commercial aspects will also be discussed.